Business
Establishment Labs to Host Investor Event for Mia Femtech on October 5, 2022
SANTA BARBARA, Calif.--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially
About this update from Establishment Labs Holdings Inc.
[{"type":"text","content":" SANTA BARBARA, Calif.--(BUSINESS WIRE)--\nEstablishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it will host an investor event on October 5, 2022 to discuss Mia Femtech® (“Mia”). A webcast of the event will begin at 4:30 p.m. Eastern Time.\n\nMia Femtech® is Establishment Labs’ minimally invasive breast aesthetics experience. The patented technologies used with Mia can increase breast size by 1 to 2 cups in a 15-minute procedure without the need for general anesthesia. The Company will provide an overview of Mia as well as updates on the progress to date in development and commercialization.\n\nEvent Details\nDate: Wednesday, October 5, 2022\nTime: 4:30 – 5:30 p.m. ET\nTo participate, please click: registration link\n\nAfter the conclusion of the program, there will be a question and answer session for investors and analysts. A recording of the event will be archived on the Company’s website.\n\nThe Company is currently pursuing regulatory approvals for Mia Femtech® in Europe and other geographies and expects to begin commercialization in select markets in the first half of 2023. Mia Femtech® is currently not approved for commercial distribution in the United States. Motiva Implants® are undergoing clinical investigation pursuant to U.S. FDA regulations for investigational medical devices.\n\nAbout Establishment Labs\n\nEstablishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, over 2.0 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora® tissue expander and Mia Femtech®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the ...